Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Retained Earnings (2016 - 2025)

United Therapeutics' Retained Earnings history spans 17 years, with the latest figure at $8.6 billion for Q4 2025.

  • For Q4 2025, Retained Earnings rose 18.48% year-over-year to $8.6 billion; the TTM value through Dec 2025 reached $8.6 billion, up 18.48%, while the annual FY2025 figure was $8.6 billion, 18.48% up from the prior year.
  • Retained Earnings for Q4 2025 was $8.6 billion at United Therapeutics, up from $100000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $8.6 billion in Q4 2025 and bottomed at -$84.1 million in Q3 2022.
  • The 5-year median for Retained Earnings is $4.3 billion (2021), against an average of $3.8 billion.
  • The largest annual shift saw Retained Earnings soared 192485.71% in 2021 before it crashed 102.0% in 2022.
  • A 5-year view of Retained Earnings shows it stood at $4.3 billion in 2021, then rose by 16.86% to $5.0 billion in 2022, then rose by 19.53% to $6.0 billion in 2023, then grew by 19.83% to $7.2 billion in 2024, then increased by 18.48% to $8.6 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Retained Earnings are $8.6 billion (Q4 2025), $100000.0 (Q3 2025), and $7.9 billion (Q2 2025).